← Back

Cooper: Cooper Companies' Q4 2025 Earnings: A Strong Finish to the Year

The Cooper Companies reported a record Q4 2025 revenue of $1.065 billion, representing a 4.6% year-over-year increase, or 3.4% on an organic basis. Non-GAAP earnings per share (EPS) came in at $1.15, beating analyst estimates of $1.11, reflecting an 11% growth. The company's gross margin decreased in Q4, but it expects operating margin leverage due to controlled SG&A growth. CooperVision's revenue was $710 million, up 4.9% or 3.2% organically, driven by the strong performance of its MyDay premium daily silicone hydrogel lens portfolio.

COO

USD 81.4

5.67%

A-Score: 2.9/10

Publication date: December 4, 2025

Full Report

Author: Analystock.ai

📋 Highlights
  • Revenue Growth Q4 revenue hit $1.065B (+4.6% YoY), while organic growth stood at 3.4%.
  • Non-GAAP Earnings Surged 11% to $1.15, reflecting strong operational performance.
  • MyDay Lens Momentum CooperVision’s MyDay portfolio neared $400M annualized, despite Clarity lens sales declining 2%.
  • Free Cash Flow & Repurchases $2.2B+ FCF target for 2026–2028 and a $2B share buyback plan announced.
  • Market Growth Outlook Contact lens market forecasted for 4–5% growth in 2026, driven by MyDay expansion and Asia-Pacific recovery.

Segment Performance

CooperVision's MyDay lens sales were particularly strong, approaching $400 million on an annualized basis. In contrast, Clarity lens sales were down a couple of percent, but the company is repositioning Clarity in certain markets to make it more entry-level. CooperSurgical revenue was $356 million, up 4% or 3.9% organically, driven by solid execution in fertility and office and surgical sales.

Guidance and Outlook

The company guided for fiscal 2026 consolidated revenues of $4.3 billion to $4.34 billion, reflecting 4.5% to 5.5% organic growth. Non-GAAP EPS is expected to be between $4.45 and $4.6 in fiscal 2026. CooperCompanies expects to generate over $2.2 billion in free cash flow from fiscal 2026 through 2028 and has raised its fiscal 2026 to 2028 free cash flow target.

Valuation and Growth Prospects

With a P/E Ratio of 43.01 and an EV/EBITDA of 19.73, the market seems to be pricing in significant growth prospects for Cooper Companies. Analysts estimate next year's revenue growth at 5.7%. The company's plans to allocate about two-thirds of its free cash flow to share repurchases in 2026, which will be EPS accretive, and its exploration of strategic alternatives, including a potential separation of its businesses, are expected to drive long-term shareholder value.

Operational Highlights

The company is undergoing a strategic review and is considering various options to create long-term value. CooperVision's free cash flow outlook improved, driven by consistent performance and working capital management. The company is also repositioning its Clarity lens product in certain markets and is optimistic about the growth prospects for its PARAGARD product.

Cooper's A-Score